[go: up one dir, main page]

WO2008080980A1 - Composition médicinale - Google Patents

Composition médicinale Download PDF

Info

Publication number
WO2008080980A1
WO2008080980A1 PCT/EP2007/064630 EP2007064630W WO2008080980A1 WO 2008080980 A1 WO2008080980 A1 WO 2008080980A1 EP 2007064630 W EP2007064630 W EP 2007064630W WO 2008080980 A1 WO2008080980 A1 WO 2008080980A1
Authority
WO
WIPO (PCT)
Prior art keywords
constituents
composition according
group
hydroxy
extract
Prior art date
Application number
PCT/EP2007/064630
Other languages
German (de)
English (en)
Inventor
Patrick Franke
Georg Roessling
Original Assignee
Patrick Franke
Georg Roessling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick Franke, Georg Roessling filed Critical Patrick Franke
Publication of WO2008080980A1 publication Critical patent/WO2008080980A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to a medicinal composition for treatment and protection of injured, excoriated and irritated animal skin according to claim 1 and its use for the manufacture of a medicament according to claim 10.
  • denatonium capsaicinate denatonium nonyl vanylamide
  • the capsaicin derivative can be added to paints, lacquers or coating compositions which might be used to coat a layer or film on an electric or optic cable, a pipe, a wall or outdoor furniture to deter animals from gnawing on or destroying it.
  • Denatonium capsaicinate may also be added to medical dressings such as bandages, to salves, creams, lotions or ointments in order to prevent animals from removing these materials by biting, gnawing, chewing or licking after procedures by the veterinarian.
  • the present medicinal composition for treatment and protection of injured, excoriated and irritated animal skin comprises
  • At least one deterrent substance for sensorial deterrence selected from the group containing pungent constituents, bitter constituents and odorants, and
  • At least one therapeutic substance selected from the group of constituents with antiseptic properties and constituents with wound healing properties.
  • composition according to the invention enables the formation of a thin protective film on the wound as well as a flavour and odour barrier preventing the animal from touching or licking the wound. Furthermore, the antiseptic and curing substances promote the wound healing process.
  • the pungent or bitter constituents of the present composition deter the animal specifically from licking the open wound by providing a pungent or bitter taste.
  • the odorant constituents provide preferably a bad smell, thus making it unpleasant for an animal to draw nearer to the open wound.
  • the pungent constituents, bitter constituents, odorant constituents, antiseptic and wound healing constituents are present at a concentration between 0 and 5 % [m/m], whereby % [m/m] relates to mass percentage.
  • the pungent substances are present at a concentration between 0,001 % [m/m] and 0,1 % [m/m].
  • the bitter constituents are preferably present in form of extracts at a concentration between 0,05 %[m/m] and 3 %[m/m].
  • the odorant constituents are preferably present at a concentration between 0 % [m/m] and 1 % [m/m].
  • the aseptic constituents as therapeutic substances are preferably present at a concentration between 0,05 %[m/m] and 1 %[m/m].
  • the wound healing constituents are preferably present at a concentration between 0 % [m/m] and 5 % [m/m].
  • the pungent constituent is preferably selected from the group containing (E)-N- (4- hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide (capsaicine), 1 -[5-(1 ,3-
  • Benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]pipehdine (piperine), 5-hydroxy-1 - (4- hydroxy-3-methoxy-phenyl) -decan-3-one (gingerol), 4-(4-hydroxy-3-methoxyphenyl)- 2-butanone (zingerone), 5-allyl-1 -methoxy-2,3-methylenedioxybenzene (myristicin) 2- propene-1 -sulfinothioic acid S-2-propenyl ester (allicin) and mustard oil.
  • the bitter constituent is preferably selected from the group comprising a flavonoide as dihydrochalcone, glycosides present in gentian extract, yarrow extract or centaury extract, isoprenoides present in hops, absinth, calamus, angelica, dandelion, hemlock, limonoids, carlinaoxide from carline thistle and (2-ethenyl-4- azabicyclo[2.2.2]oct-5-yl)- (6-methoxyquinolin-4-yl)-methanol (quinine).
  • at least one of these constituents is combined with the bitter tasting substances glyceryl caprylate and/or polyglyceryl 10-laurate.
  • the bitter constituent comprises glycerlyl caprylate and / or polyglyceryl 10-laurate.
  • the odorants is preferably selected from the group of containing aromatic substances, preferably essential oils from lemon balm, Melissae folium, Menthae arvensis and Methae piperitae.
  • the therapeutic substance with antiseptic and wound healing properties is preferably selected form the group comprising Myroxylum balsamum (Peru ageratum), chlorohexidine, colloidal silver (argent), silver nanoparticles, 5-chloro-2-(2,4- dichlorophenoxy)-phenol (triclosan), ethacridine lactate, extracts from Centella asiatica, willow bark, birch, olive leafs, tea-tree, Aloe vera, calendula, passion flower, hamamelis, camomile, bearberry, licorice, 18 ⁇ -glycyrhetine acid or mixtures thereof, polysaccharides as lichenine, isolichenine and lichen acid from Lichen islandicus, Plantaginis lanceolatae folium, Uvae ursi folium, Myrrha, Arnicae flos and Equiseti herba.
  • Myroxylum balsamum Peru ageratum
  • chlorohexidine colloidal silver (argent
  • the present composition comprises also at least one astringent constituent, preferably selected from the group comprising tannins such as tannins from Quercus robur or Syzygium cumini, flavanoides such as epigallocatechin-3- gallate, proanthocyanidines, flavonoles such as quercitine glycosides in Gossypium, quinine as 5-Hydroxy-1 ,4-naphthalindion (juglon) from Carya ovata, aluminium compounds such as aluminium chlorohydrate, aluminium alkali sulphate, aluminium hydroxid acetate hydrate, ammoniumchlohde, colloidal silver, extract from blackberry leafs, extracts from green tee, black tea, Krameria triandra and Rhizoma tormentillae.
  • the astringent constituents are preferably present in form of extracts at a concentration between 0,5 %[m/m] and 5 %[m/m].
  • the present composition might be applied directly onto the wound or the wound edge in form of emulsion, emulsifying gel, semisolid or liquid formulation, salves, medical dressings, plaster, compress, gauze, film forming polymeric solution or another polymer carrier.
  • the composition may also be sprayed onto the wound in form of a liquid vehicle.
  • An emulsifying gel preferably comprises
  • polyacrylate as Ultrez 10 or Carbopol
  • a film forming polymer composition preferably comprises
  • the medicinal composition according to the invention is also used for the manufacture of a medicament for the treatment of wounds, excoriated or irritated skin of animals, especially of dogs.
  • Example 1 describes an emulsifying gel for application on the wound edge.
  • polyacrylate as Ultrez 10 or Carbopol 980
  • a mixing vessel is filled with 650 g Aqua Purificata. 20 g Tannin is added to the water. The mixture is stirred at a temperature of 25°C ⁇ 5°C till a clear yellow solution is formed.
  • a beaker is filled with 45 g MCT, 1 g lemon balm oil, 15 g Cremophor RH40 and mixed at a temperature of 25°C ⁇ 5°C.
  • the Capsaicin solution is added to the water phase while stirring. Then, the lipid phase is mixed into the water phase. The obtained mixture is homogenized at a vacuum of - 0,8 bar at a temperature of 25°C ⁇ 5°C. After 5 minutes the mixture is aerated carefully.
  • Polyacrylic acid for example Ultrez 10 or Carbopol 980
  • Ultrez 10 or Carbopol 980 is added to the above mixture while vigorous stirring for a time period of 5 min.
  • the pH value is adjusted to 5-6 by adding 60 g of a 5% NaOH solution under vigorous stirring.
  • the obtained mixture is homogenized at a vacuum of - 0,8 bar at a temperature of 25°C ⁇ 5°C. After 2 minutes the mixture is carefully aerated and water is added up to total weight of 940 g of the mixture while maintaining the pH.
  • Example 2 describes a film forming polymer composition for application onto the wound.
  • Chlorhexidindigluconate, Oleum Absinthii and ribwort extract are dissolved in ethanol.
  • the silicon gum is dissolved in Q7-9180 fluid and 193 Fluid.
  • both solutions are unified under constant stirring.
  • the amount of ethanol can be adapted to the solubility of the plant extracts in the silicon media.
  • the composition can be applied with a brush or a spray applicator. Within minutes a flexible, dry film is formed on the animal skin.
  • Example 3 describes further recipes for medicinal compositions according to the present invention that can be obtained according to the principles outlined above.
  • lemon balm oil (oleum melissae indicum, cymbopogon wintehanus)
  • camelia sinensis extract green tea extract, polyphenols >80%
  • solvent propylene glycol and/or ethylalcohol (and/or up to 15 g aqua puhficata), if necessary for solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition médicinale destinée au traitement et à la protection d'une peau blessée, écorchée et irritée. La composition de l'invention comprend - au moins une substance faisant office de répulsif sensoriel, sélectionnée dans le groupe contenant des éléments piquants, des éléments amers et des éléments odorants, et - au moins une substance thérapeutique sélectionnée dans le groupe contenant des substances possédant des propriétés antiseptiques et des substances possédant des propriétés cicatrisantes. L'invention concerne également l'utilisation de cette composition pour la fabrication d'un médicament destiné au traitement et à la protection d'une peau blessée, écorchée et irritée. L'invention est particulièrement utile pour le traitement d'animaux.
PCT/EP2007/064630 2006-12-29 2007-12-28 Composition médicinale WO2008080980A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090226 2006-12-29
EP06090226.9 2006-12-29

Publications (1)

Publication Number Publication Date
WO2008080980A1 true WO2008080980A1 (fr) 2008-07-10

Family

ID=39400933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/064630 WO2008080980A1 (fr) 2006-12-29 2007-12-28 Composition médicinale

Country Status (1)

Country Link
WO (1) WO2008080980A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057991A1 (en) * 2011-04-01 2014-02-27 L'oreal Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone
WO2015180697A1 (fr) * 2014-05-26 2015-12-03 Biotd Sociedad Anonima Gel avec nanoparticules d'argent, utilisation médicale et procédé pour son obtention
JP2020512409A (ja) * 2017-03-30 2020-04-23 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891919A (en) * 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6274555B1 (en) * 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
US6294205B1 (en) * 1999-11-29 2001-09-25 Brenda Jean Hollenbeck Botanical composition for soothing skin
WO2004103073A1 (fr) * 2003-05-16 2004-12-02 Pearson Research And Development Limited Procedes et compositions a base d'huile d'emeu

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891919A (en) * 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6294205B1 (en) * 1999-11-29 2001-09-25 Brenda Jean Hollenbeck Botanical composition for soothing skin
US6274555B1 (en) * 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
WO2004103073A1 (fr) * 2003-05-16 2004-12-02 Pearson Research And Development Limited Procedes et compositions a base d'huile d'emeu

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057991A1 (en) * 2011-04-01 2014-02-27 L'oreal Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone
WO2015180697A1 (fr) * 2014-05-26 2015-12-03 Biotd Sociedad Anonima Gel avec nanoparticules d'argent, utilisation médicale et procédé pour son obtention
JP2020512409A (ja) * 2017-03-30 2020-04-23 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
JP7113540B2 (ja) 2017-03-30 2022-08-05 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
JP2022153490A (ja) * 2017-03-30 2022-10-12 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
JP7411266B2 (ja) 2017-03-30 2024-01-11 ファイト ソフォス リミテッド 創傷および他の皮膚症状の治療に用いられる植物抽出物と組み合わせたコロイド銀
US12128128B2 (en) 2017-03-30 2024-10-29 Phyto Sophos Ltd. Colloidal silver combined with plant extracts for use in treating wounds and other skin conditions

Similar Documents

Publication Publication Date Title
DE69838947T2 (de) Wasser/ethanol pflanzenextrakte aus centipeda cunninghamii
US9061049B2 (en) Antifungal, antibacterial topical composition for the prevention and treatment of various skin conditions including diaper rash
JP2002536398A (ja) 皮膚消毒剤組成物
CA2974166C (fr) Dispersion microbicide huile dans eau
CA2850908C (fr) Composition antimicrobienne aqueuse contenant des acides resiniques de coniferes
RU2538689C2 (ru) Композиция для доставки удерживаемого углеводом активного агента и изделия, в которых она применяется
JP2003525205A (ja) 亜鉛含有歯磨剤組成物
CN101686958B (zh) 治疗指甲疾病的局部杀真菌药物
TW201200161A (en) Oral compositions containing extracts of Zizyphus joazeiro and related methods
CN101453900A (zh) 啤酒花树脂的水溶性药物组合物
CN102762259A (zh) 含有倒捻子提取物的口腔组合物及相关方法
US20230087131A1 (en) Liquid dressing compositions and their veterinary uses
TWI662895B (zh) 粉末狀害蟲忌避組成物之用途及其製造方法
WO2008080980A1 (fr) Composition médicinale
CN1980631A (zh) 用于制备水包油乳液的高浓缩自乳化乳液基质
KR20010031128A (ko) 탈모 방지 및 치료용 화장품 제재
WO2002098404A1 (fr) Compositions topiques pour utilisations en medecine veterinaire
JP2021023510A (ja) 固形消臭剤
US20070237737A1 (en) Formulation and method for a skin treatment for animals
JP2001348324A (ja) 水性皮膚清浄剤
CA3176555A1 (fr) Menthol stabilise et autres compositions de composes volatils et procedes
JP5038683B2 (ja) 動物の外部寄生虫防除剤
US20160045412A1 (en) Antifungal, antibacterial topical composition for the prevention and treatment of various skin conditions including diaper rash
JP2003160502A (ja) 木酢液から有効画分を製造する方法とその利用
US8491941B1 (en) Rash treatment with scar prevention

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07866325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07866325

Country of ref document: EP

Kind code of ref document: A1